Zacks Investment Research cut shares of Natera, Inc. (NASDAQ:NTRA) from a hold rating to a sell rating in a research note issued to investors on Tuesday.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

Other equities research analysts have also recently issued research reports about the company. Cowen and Company reissued a buy rating and set a $14.00 target price on shares of Natera in a report on Friday, September 1st. ValuEngine raised Natera from a strong sell rating to a sell rating in a report on Thursday, August 10th. BidaskClub cut Natera from a buy rating to a hold rating in a report on Tuesday, July 25th. Morgan Stanley dropped their price target on Natera from $18.00 to $13.00 and set an overweight rating on the stock in a report on Monday, August 7th. Finally, Robert W. Baird reaffirmed a buy rating on shares of Natera in a report on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $15.00.

Shares of Natera (NTRA) traded up $0.02 during trading hours on Tuesday, reaching $9.36. The company had a trading volume of 149,500 shares, compared to its average volume of 199,594. Natera has a 1 year low of $7.35 and a 1 year high of $14.76. The company has a current ratio of 1.85, a quick ratio of 1.75 and a debt-to-equity ratio of 2.43.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, November 8th. The medical research company reported ($0.51) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.04). Natera had a negative return on equity of 197.09% and a negative net margin of 62.34%. The firm had revenue of $56.66 million for the quarter, compared to the consensus estimate of $55.31 million. During the same period in the previous year, the firm earned ($0.50) EPS. Natera’s revenue for the quarter was up 5.1% on a year-over-year basis. analysts anticipate that Natera will post -2.12 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Natera, Inc. (NTRA) Downgraded by Zacks Investment Research to “Sell”” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/15/natera-inc-ntra-downgraded-by-zacks-investment-research-to-sell.html.

In other Natera news, insider Jonathan Sheena sold 120,000 shares of the company’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total value of $1,504,800.00. Following the transaction, the insider now owns 533,208 shares of the company’s stock, valued at $6,686,428.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 12.57% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN increased its holdings in shares of Natera by 2.8% in the second quarter. Wells Fargo & Company MN now owns 18,031 shares of the medical research company’s stock valued at $195,000 after buying an additional 491 shares in the last quarter. Principal Financial Group Inc. grew its position in Natera by 0.6% during the 1st quarter. Principal Financial Group Inc. now owns 111,278 shares of the medical research company’s stock worth $987,000 after purchasing an additional 688 shares in the last quarter. American International Group Inc. grew its position in Natera by 7.1% during the 1st quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock worth $142,000 after purchasing an additional 1,068 shares in the last quarter. Alliancebernstein L.P. grew its position in Natera by 5.6% during the 1st quarter. Alliancebernstein L.P. now owns 26,600 shares of the medical research company’s stock worth $236,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Voya Investment Management LLC grew its position in Natera by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock worth $159,000 after purchasing an additional 2,212 shares in the last quarter. 60.54% of the stock is currently owned by institutional investors.

About Natera

Receive News & Stock Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related stocks with our FREE daily email newsletter.